person reading

About Neuphoria Therapeutics Inc. - Company Information, Overview, History and Profile

What does Neuphoria Therapeutics Inc. do?

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.

Neuphoria Therapeutics Inc. Management structure

All Gross Remunerations are in USD
Mr. Timothy M. Cunningham
Chief Financial Officer
-
2024
Gross Remuneration
Year
Mr. Adrian Hinton
Financial Controller and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Dr. Spyros Papapetropoulos, PhD
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year

Neuphoria Therapeutics Inc. Board of directors

All Gross Remunerations are in USD
Mr. Aaron N. D. Weaver
Independent Director
-
2025
Gross Remuneration
Year